Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Replimune Group (Nasdaq: REPL), a clinical stage biotechnology company focused on developing novel oncolytic immunotherapies, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team will deliver a presentation on Monday, January 13, 2025, at 2:15 PM PT.
The presentation will be accessible through a simultaneous webcast in the Investors section of Replimune's website at replimune.com. For those unable to attend live, a replay option will remain available for 30 days after the conference.
Replimune Group (Nasdaq: REPL), una compagnia biotecnologica in fase clinica focalizzata sullo sviluppo di nuove immunoterapie oncolitiche, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. Il team di gestione dell'azienda presenterà un intervento lunedì 13 gennaio 2025, alle 14:15 PT.
La presentazione sarà accessibile tramite una trasmissione in diretta nella sezione Investitori del sito web di Replimune all'indirizzo replimune.com. Per coloro che non possono partecipare dal vivo, sarà disponibile un'opzione di replica per 30 giorni dopo la conferenza.
Replimune Group (Nasdaq: REPL), una empresa de biotecnología en etapa clínica enfocada en desarrollar nuevas inmunoterapias oncolíticas, ha anunciado su participación en la 43ª Conferencia Anual de J.P. Morgan Healthcare. El equipo de gestión de la empresa realizará una presentación el lunes 13 de enero de 2025, a las 14:15 PT.
La presentación estará accesible a través de una transmisión web simultánea en la sección de Inversores del sito web de Replimune en replimune.com. Para aquellos que no puedan asistir en vivo, habrá una opción de repetición disponible durante 30 días después de la conferencia.
Replimune Group (Nasdaq: REPL), 새로운 종양 면역 치료제를 개발하는 임상 단계의 생명공학 회사가 제43회 JP모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사 관리 팀은 2025년 1월 13일 월요일 오후 2시 15분 PT에 발표를 진행할 예정입니다.
발표는 Replimune의 웹사이트의 투자자 섹션에서 실시간 웹캐스트를 통해 접근할 수 있습니다. 라이브로 참석할 수 없는 분들을 위해, 컨퍼런스 후 30일 동안 다시 보기 옵션이 제공됩니다.
Replimune Group (Nasdaq: REPL), une entreprise de biotechnologie en phase clinique axée sur le développement de nouvelles immunothérapies oncolytiques, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare. L'équipe de direction de l'entreprise fera une présentation le lundi 13 janvier 2025, à 14h15 PT.
La présentation sera accessible via un webinaire simultané dans la section Investisseurs du site Web de Replimune à l'adresse replimune.com. Pour ceux qui ne peuvent pas assister en direct, une option de rediffusion sera disponible pendant 30 jours après la conférence.
Replimune Group (Nasdaq: REPL), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung neuartiger onkolytischer Immuntherapien spezialisiert hat, hat seine Teilnahme an der 43. jährlichen JP Morgan Healthcare-Konferenz bekannt gegeben. Das Management-Team des Unternehmens wird am Montag, den 13. Januar 2025, um 14:15 Uhr PT eine Präsentation halten.
Die Präsentation wird über einen gleichzeitigen Webcast im Bereich 'Investoren' der Replimune-Website unter replimune.com zugänglich sein. Für diejenigen, die nicht live teilnehmen können, bleibt eine Wiederholungsoption für 30 Tage nach der Konferenz verfügbar.
- None.
- None.
WOBURN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 2:15 PM PT.
A simultaneous webcast will be available in the Investors section of Replimune’s website at replimune.com. A replay will be available for 30 days following the conference.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit replimune.com.
Investor Inquiries
Chris Brinzey
ICR Healthcare
339.970.2843
chris.brinzey@icrhealthcare.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
FAQ
When is Replimune (REPL) presenting at the 2025 J.P. Morgan Healthcare Conference?
How long will the replay of Replimune's (REPL) J.P. Morgan Healthcare Conference presentation be available?
Where can investors watch Replimune's (REPL) J.P. Morgan Healthcare Conference presentation?
What type of therapies is Replimune (REPL) developing as presented at the J.P. Morgan Healthcare Conference?
